logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
K

Kangsheng Gu

the first affiliated hospital of anhui medical university
H指数:37
被引数:8,142

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Dynamic monitoring of circulating tumor cells and PD-L1 combined positive score as prognostic biomarkers for adjuvant immunochemotherapy in stage III gastric cancer: A prospective observational study

动态监测循环肿瘤细胞和PD-L1联合阳性评分作为III期胃癌辅助免疫化疗预后生物标志物的前瞻性观察研究

International Immunopharmacology
IF4.7
2026-06-270
PRE
Xiaoyu Guo; Ziting Qu; Yuyan Wang; Luyao Huang; Mengting Cheng; Nana Huang; Xiaoli Wei; Kangsheng Gu; Yiyin Zhang
Camrelizumab-based therapies for the treatment of advanced lung cancer: a prospective, open-label, multicenter, observational, real-world study

基于Camrelizumab的治疗晚期肺癌的疗法：一项前瞻性、开放标签、多中心、观察性、真实世界研究

FRONTIERS IN IMMUNOLOGY
IF5.9
2025-03-070
OA
Zhao, Dong; Bi, Minghong; Cheng, Xiaofei; Wang, Shuhong; Cheng, Huaidong; Xia, Xiaoyang; Chen, Huan; Zhang, Yanbei; Hu, Zhiqiang; Cao, Qisheng; Liang, Hui; Wang, Fan; Min, Xuhong; Xu, Ling; Feng, Kehai; Zhou, Jinhua; Li, Xinzhong; Wang, Rui; Xie, Hua; Chen, Xiaosi; Gu, Kangsheng
[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-249.

[1] Sung H, Ferlay J, Siegel RL, 等. 全球癌症统计数据2020：185个国家36种癌症的全球发病率与死亡率GLOBOCAN估算. CA Cancer J Clin 2021;71:209-249.

JHEP REPORTS
IF7.5
2025-02-010
PRE
Finn, Richard S.; Gu, Kangsheng; Chen, Xi; Merle, Philippe; Lee, Kyung-Hun; Bouattour, Mohamed; Cao, Peiguo; Wang, Wei; Cheng, Ann-Lii; Zhu, Liangjun; Lim, Ho Yeong; Kudo, Masatoshi; Pan, Yueyin; Chang, Ting-Tsung; Edeline, Julien; Li, Wei; Yang, Ping; Li, Chen; Li, Jianfeng; Siegel, Abby B.; Qin, Shukui
The efficacy and safety of suvemcitug, envafolimab, and FOLFIRI in microsatellite-stable or mismatch repair-proficient colorectal cancer: preliminary results of a phase 2 study

suvemcitug、envafolimab和FOLFIRI在微卫星稳定或错配修复 proficient 结直肠癌中的有效性与安全性：一项2期研究的初步结果

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
IF2.3
2025-01-210
OA
Liu, Ying; Wang, Jufeng; Fang, Yong; Deng, Yanhong; Hu, Changlu; Fan, Qingxia; Gu, Kangsheng; Zhang, Yu; Yang, Chen; Liu, Zhenru; Tian, Ji; Sun, Xiyang; Sun, Shuguang
A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer
FUTURE ONCOLOGY
IF2.6
2024-12-040
OAAI
Jiang, Zefei; Ouyang, Quchang; Sun, Tao; Zhang, Qingyuan; Teng, Yuee; Cui, Jiuwei; Wang, Haibo; Yin, Yongmei; Wang, Xiaojia; Zhou, Xin; Wang, Yongsheng; Sun, Gang; Wang, Jingfen; Zhang, Lili; Yang, Jin; Qian, Jun; Yan, Min; Liu, Xinlan; Yi, Tienan; Cheng, Ying; Li, Man; Zang, Aimin; Wang, Shusen; Wang, Chuan; Wu, Xinhong; Cheng, Jing; Li, Hui; Lin, Ying; Geng, Cuizhi; Gu, Kangsheng; Xie, Chunwei; Xiong, Huihua; Wu, Xiaohong; Yang, Junlan; Li, Qingshan; Chen, Yiding; Li, Fanfan; Zhang, Anqin; Zhang, Yongqiang; Wu, Yudong; Nie, Jianyun; Liu, Qiang; Wang, Kun; Mo, Xueli; Chen, Lilin; Pan, Yueyin; Fu, Peifen; Zhang, Helong; Pang, Danmei; Sheng, Yuan; Han, Yunwei; Wang, Hongxia; Cang, Shundong; Luo, Xianming; Yu, Wenbo; Deng, Rong; Yang, Chaoqiang; Keegan, Patricia
Real-world treatment (Tx) patterns in patients (pts) with HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (HER2+aGC/GEJC) in East Asia (HER2+GASTA)

东亚地区人表皮生长因子受体2阳性局部晚期或转移性胃或胃食管结合部腺癌（HER2+aGC/GEJC）患者的真实世界治疗（Tx）模式（HER2+GASTA）

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Oh, D-Y.; Yeo, W.; Chen, J-S.; Ba, Y.; Chan, W. W. L.; Chen, M-J.; Chen, Y. H.; Gu, K.; Hung, Y-P.; Kim, J. G.; Lee, J.; Liang, X.; Luo, S.; Rha, S. Y.; Yuan, Y.; Kim, T.; Yanagida, M.; Sato, R.; Xu, R-H.
Efficacy and Safety of Biosimilar SCT510 Compared with Bevacizumab for the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study
ADVANCES IN THERAPY
IF4
2024-09-040
PRE
Cheng, Ying; Pan, Zhanyu; Wu, Lin; Zhu, Bo; Yu, Yan; Zang, Kai; Zhuang, Wu; Liu, Lianke; Gu, Kangsheng; Lian, Juanwen; Chen, Rixin; Bian, Tao; Lin, Dang; Sun, Shenghua; Li, Wei; Hang, Xiaosheng; Jiang, Ou; Zhong, Fukuan; Wang, Rui; Luo, Hui; Shi, Huaqiu; Wei, Zonghui; Zhao, Li; Chen, Shaoshui; Sun, Hongmei; Li, Xingya; Sun, Debin; Ren, Tiejun; Lei, Kaijian; He, Miao; Li, Gaofeng; Liu, Hailong; Li, Runpu; Hu, Chunhong; Kong, Li; Sun, Meili; Xie, Liangzhi; Gai, Wenlin; Chen, Weiqiu; Huang, Zhe; Ren, Wenwen; Su, Huo
Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial

camrelizumab联合化疗治疗未经治疗的晚期或转移性食管鳞状细胞癌的最终分析: ESCORT-1st试验

MED
IF11.8
2024-09-011
PRE
He, Mingming; Wang, Zhiqiang; Lu, Jin; Bai, Yuxian; Mao, Teng; Wang, Jun; Fan, Qingxia; Zhang, Yiping; Zhao, Kuaile; Chen, Zhendong; Gao, Shegan; Li, Jiancheng; Fu, Zhichao; Gu, Kangsheng; Liu, Zhihua; Wu, Lin; Zhang, Xiaodong; Feng, Jifeng; Niu, Zuoxing; Ba, Yi; Zhang, Helong; Liu, Ying; Zhang, Li; Min, Xuhong; Huang, Jing; Cheng, Ying; Wang, Dong; Sheng, Zhen; Zeng, Wanqin; Song, Li; Xu, Rui-Hua; Luo, Huiyan
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial
NATURE MEDICINE
IF50
2024-07-1112
OAAI
Cheng, Ying; Chen, Jianhua; Zhang, Wei; Xie, Chao; Hu, Qun; Zhou, Ningning; Huang, Chun; Wei, Shihong; Sun, Hong; Li, Xingya; Yu, Yan; Lai, Jinhuo; Yang, Huaping; Fang, Haohui; Chen, Hualin; Zhang, Peng; Gu, Kangsheng; Wang, Qiming; Shi, Jianhua; Yi, Tienan; Xu, Xingxiang; Ye, Xianwei; Wang, Daqing; Xie, Conghua; Liu, Chunling; Zheng, Yulong; Lin, Daren; Zhuang, Wu; Lu, Ping; Yu, Guohua; Li, Jinzhang; Gu, Yuhai; Li, Baolan; Wu, Rong; Jiang, Ou; Wang, Zaiyi; Wu, Guowu; Lin, Haifeng; Zhong, Diansheng; Xu, Yanhua; Shu, Yongqian; Wu, Di; Chen, Xingwu; Wang, Jie; Wang, Minghui; Yang, Runxiang
SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study

基于SALIRI的 (雷替曲塞联合伊立替康) 疗法作为转移性结直肠癌患者的二线治疗 (SALLY): 一项前瞻性，多中心，非干预性，注册研究

CANCER COMMUNICATIONS
IF24.9
2024-07-080
OAAI
Qin, Shuqui; Li, Jin; Zhou, Aiping; Zhang, Yanqiao; Yuan, Xianglin; Zhu, Liangjun; Qin, Baoli; Zeng, Shan; Shen, Lin; Yuan, Ying; Wang, Weibo; Liang, Jun; Zhang, Xianwen; Ye, Feng; Chen, Ping; Wang, Huaizhang; Yu, Zhenyan; Yue, Lu; Fang, Yong; Xiong, Jianping; Yang, Jianwei; Wan, Yiye; Yin, Xianli; Wang, Wenling; Xu, Nong; Wang, Xiaohong; Xiao, Zemin; Su, Huafang; Wang, Ying; Gu, Kangsheng; Tu, Shuiping; Wang, Zishu; Liu, Bo; Hu, Xiaohua; Liu, Weixian; Li, Xiaofeng
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial

Fruquintinib联合紫杉醇与安慰剂联合紫杉醇治疗胃或胃食管交界处腺癌的比较: FRUTIGA随机3期试验

NATURE MEDICINE
IF50
2024-06-011
PRE
Wang, Feng; Shen, Lin; Guo, Weijian; Liu, Tianshu; Li, Jin; Qin, Shukui; Bai, Yuxian; Chen, Zhendong; Wang, Jufeng; Pan, Yueyin; Shu, Yongqian; Zhao, Fuyou; Cheng, Ying; Ye, Feng; Gu, Kangsheng; Zhang, Tao; Pan, Hongming; Zhong, Haijun; Zhou, Fuxiang; Qin, Yanru; Yang, Lei; Mao, Weidong; Li, Qiu; Dai, Wenxiang; Li, Wei; Wang, Shubin; Tang, Yong; Ma, Dong; Yin, Xianli; Deng, Yanhong; Yuan, Ying; Li, Man; Hu, Wenwei; Chen, Donghui; Li, Guoxin; Liu, Qiqi; Tan, Panfeng; Fan, Songhua; Shi, Michael; Su, Weiguo; Xu, Rui-Hua
A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter, cross-sectional study
CANCER
IF5.1
2024-03-221
OAAI
Chen, Meiting; Li, Lu; Xia, Qing; Chen, Xiaobing; Liao, Zijun; Wang, Chang; Shen, Bo; Zhou, Min; Zhang, Qingyuan; Zhang, Yanqiao; Qian, Liting; Yuan, Xianglin; Wang, Zhehai; Xue, Cong; An, Xin; Liu, Bin; Gu, Kangsheng; Hou, Mei; Wang, Xiaojia; Wang, Wei; Li, Enxiao; Zhong, Jincai; Cheng, Jing; Shu, Yongqian; Yang, Nong; Wang, Huaqing; Yang, Runxiang; Liu, Tianshu; Deng, Ting; Ma, Fei; Liao, Wangjun; Qiu, Wensheng; Chen, Yu; Chen, Xi; Zhang, Mingzhi; Xu, Ruilian; Li, Xiaoling; Feng, Jifeng; Ba, Yi; Shi, Yanxia
Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase II study

抗EGFR单克隆抗体SCT200在氟尿嘧啶，伊立替康和奥沙利铂难治性RAS和BRAF野生型转移性结直肠癌患者中的疗效，安全性和基因组分析: II期研究

EBIOMEDICINE
IF10.8
2024-02-010
OAAI
Yang, Lin; Zhang, Wen; Fan, Nanfeng; Cao, Peiguo; Cheng, Ying; Zhu, Lingjun; Luo, Suxia; Zong, Hong; Bai, Yuxian; Zhou, Jianfeng; Deng, Yanhong; Ba, Yi; Liu, Tianshu; Aili, Mayinuer; Yin, Xianli; Gu, Kangsheng; Dai, Guanghai; Ying, Jieer; Shi, Jianhua; Gao, Yajie; Li, Wei; Yu, Guohua; Xie, Liangzhi; Gai, Wenlin; Wang, Yan; Meng, Peng; Shi, Yuankai
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial

Toripalimab联合nab-紫杉醇治疗转移性或复发性三阴性乳腺癌: 一项随机3期试验

NATURE MEDICINE
IF50
2024-01-0827
PRE
Jiang, Zefei; Ouyang, Quchang; Sun, Tao; Zhang, Qingyuan; Teng, Yuee; Cui, Jiuwei; Wang, Haibo; Yin, Yongmei; Wang, Xiaojia; Zhou, Xin; Wang, Yongsheng; Sun, Gang; Wang, Jingfen; Zhang, Lili; Yang, Jin; Qian, Jun; Yan, Min; Liu, Xinlan; Yi, Tienan; Cheng, Ying; Li, Man; Zang, Aimin; Wang, Shusen; Wang, Chuan; Wu, Xinhong; Cheng, Jing; Li, Hui; Lin, Ying; Geng, Cuizhi; Gu, Kangsheng; Xie, Chunwei; Xiong, Huihua; Wu, Xiaohong; Yang, Junlan; Li, Qingshan; Chen, Yiding; Li, Fanfan; Zhang, Anqin; Zhang, Yongqiang; Wu, Yudong; Nie, Jianyun; Liu, Qiang; Wang, Kun; Mo, Xueli; Chen, Lilin; Pan, Yueyin; Fu, Peifen; Zhang, Helong; Pang, Danmei; Sheng, Yuan; Han, Yunwei; Wang, Hongxia; Cang, Shundong; Luo, Xianming; Yu, Wenbo; Deng, Rong; Yang, Chaoqiang; Keegan, Patricia

研究方向

暂未获取到该数据
Y
Yiyin Zhang
H 指数:31论文数:151被引数:3,380
Y
Yueyin Pan
H 指数:45论文数:286被引数:1.0万
Y
Yuxian Bai
H 指数:59论文数:366被引数:1.9万
J
Jiuwei Cui
H 指数:58论文数:641被引数:1.5万
程
程颖
H 指数:84论文数:1,042被引数:4.5万
S
Shukui Qin
H 指数:76论文数:578被引数:5.1万
王
王华
H 指数:113论文数:1,639被引数:5.8万
Z
Ziting Qu
H 指数:4论文数:12被引数:83
S
Shundong Cang
H 指数:36论文数:179被引数:7,184
J
Jianming Xu
H 指数:56论文数:387被引数:2.6万